Biosimilars Market Overview

The report is titled as ‘Biosimilars Market: Opportunity Analysis and Future Assessment 2020-2028’. An overview of conceptual frameworks, analytical approaches of the biosimilars market is the main objective of the report, which further consists the market opportunity and insights of the data involved in the making of the respective market. Biosimilars market is expected to grow with a significant rate in the near future.

The global biosimilars market in 2020 is estimated for more than US$ 11,036.2 Mn and expected to reach a value of US$ 1,09,501.8 Mn by 2028 with a significant CAGR of 33.5%.

MMC Overview

The non-identical approach of Meridian Market Consultants stands with conceptual methods backed up with the data analysis. The novel market understanding approach makes up the standard of the assessment results that give a better opportunity for the customers to put their effort.

A research report on the biosimilars market by Meridian Market Consultants is an in-depth and extensive study of the market based on the necessary data crunching and statistical analysis. It provides a brief view of the dynamics flowing through the market, which includes the factors that support market and the factors that are acting as impedance for the growth of the market. Furthermore, the report includes the various trends and opportunities in the respective market in different regions for a better understanding of readers that helps to analyze the potential of the market.

Biosimilars Market Key Players

Some of the key participating players in global Biosimilars market are:

    Pfizer

    Sandoz International

    Teva Pharmaceuticals

    Amgen

    Biocon

    Dr. Reddy’s Laboratories

    Celltrion

    Samsung Biologics

    Synthon Pharmaceuticals, Inc.

    LG Life Sciences

    Biocon

    Hospira

    Merck Serono (Merck Group)

    Biogen Idec Inc.

    Genentech (Roche Group)

Biosimilars Market Segmentation

The global Biosimilars market is segmented on the basis of product type, manufacturing, diseases, and region.

By Product Type

    Recombinant Non-Glycosylated Proteins

    Recombinant Human Growth Hormone (RHGH)

    Granulocyte Colony-Stimulating Factor (Filgrastim)

    Insulin

    Interferons

o    Interferon-Beta

o    Interferon-Alpha

    Recombinant Glycosylated Proteins

    Erythropoietin (EPO)

    Monoclonal Antibodies (MABS)

o    Infliximab

o    Rituximab

o    Adalimumab

o    Other Monoclonal Antibodies

    Follitropin

    Recombinant Peptides

    Glucagon

    Calcitonin

By Type of Manufacturing

    In-House Manufacturing

    Contract Manufacturing

By Disease

    Oncology

    Chronic Diseases

    Autoimmune Diseases

    Blood Disorders

    Growth Hormone Deficiency

    Infectious Diseases

    Other Diseases

By Region

    North America

    Latin America

    Europe

    Asia Pacific

    Middle East

    Africa

Biosimilars Market Dynamics

Patent expiration in the biological drug industry is the major factor driving the growth of global biosimilars market. Moreover, the introduction of clear regulatory pathways for the introduction of biosimilars to the market by many countries is further encouraging biosimilar development. For instance, recently India and Canada introduced regulations for approval of biosimilar drugs in respective countries. However, unlike generic chemical entities, producing identical copies of innovator cell-based drugs is impossible and takes more time, which is the biggest challenge for the growth of global biosimilars market. Biologics are produced by cells in culture or whole organisms, which are inherently more variable than chemical synthesis methods.     

Biosimilars Market Regional Overview

On the basis of region, the global biosimilars market is segmented into six regions namely North America, Latin America, Asia Pacific, Europe, Middle East, and Africa. North America biosimilars market is expected to be the most dominating market throughout the forecast period due to due to the expiry of patents for blockbuster biological drugs. The presence of key players in Europe makes it second-largest market for biosimilars. Asia Pacific biosimilars market is expected to witness delayed growth due to relatively long patent term for biological drugs

1.    Global Biosimilar Market Report Overview

1.1.    Introduction

1.2.    Report Description

1.3.    Methodology

2.    Global Biosimilar Market Overview

2.1.    Introduction

2.1.1.    Market Definition

2.1.2.    Market Taxonomy

2.2.    Executive Summary

2.3.    Global Biosimilar Market Snapshot

2.4.    Global Biosimilar Market Size and Forecast, 2020–2028

2.4.1.    Introduction

2.4.2.    Market Value Forecast and Annual Growth Rate (AGR) Comparison (2020–2028)

2.5.    Global Biosimilar Market Dynamics

2.5.1.    Drivers

2.5.2.    Restraints

2.5.3.    Opportunity

2.5.4.    Trends

2.6.    Key Regulations

2.7.    Porter’s Five Forces Model

3.    Global Biosimilar Market, By Product Type

3.1.    Introduction

3.1.1.    Annual Growth Rate Comparison, By Product Type

3.1.2.    BPS Analysis, By Product Type

3.2.    Market Revenue (US$Mn) Forecast, By Product Type

3.2.1.    Recombinant Non-Glycosylated Proteins

3.2.2.    Recombinant Human Growth Hormone (RHGH)

3.2.3.    Granulocyte Colony-Stimulating Factor (Filgrastim)

3.2.4.    Insulin

3.2.5.    Interferons

3.2.5.1.    Interferon-Beta

3.2.5.2.    Interferon-Alpha

3.2.6.    Recombinant Glycosylated Proteins

3.2.6.1.    Erythropoietin (EPO)

3.2.6.2.    Monoclonal Antibodies (MABS)

3.2.6.2.1.    Infliximab

3.2.6.2.2.    Rituximab

3.2.6.2.3.    Adalimumab

3.2.6.2.4.    Other Monoclonal Antibodies

3.2.6.3.    Follitropin

3.2.7.    Recombinant Peptides

3.2.7.1.    Glucagon

3.2.7.2.    Calcitonin

3.3.    Global Biosimilar Market Attractiveness Index, By Product Type

4.    Global Biosimilar Market, By Type of Manufacturing

4.1.    Introduction

4.1.1.    Annual Growth Rate Comparison, By Type of Manufacturing

4.1.2.    BPS Analysis, By Type of Manufacturing

4.2.    Market Revenue (US$Mn) Forecast, By Type of Manufacturing

4.2.1.    In-House Manufacturing

4.2.2.    Contract Manufacturing

4.3.    Global Biosimilar Market Attractiveness Index, By Type of Manufacturing

5.    Global Biosimilar Market, By Diseases

5.1.    Introduction

5.1.1.    Annual Growth Rate Comparison, By Diseases

5.1.2.    BPS Analysis, By On the Basis of Diseases

5.2.    Market Revenue (US$Mn) Forecast, By Diseases

5.2.1.    Oncology

5.2.2.    Chronic Disease

5.2.3.    Autoimmune Disorder

5.2.4.    Blood Disorders

5.2.5.    Growth Hormone Disorders

5.2.6.    Infectious Disorder

5.2.7.    Others

5.3.    Global Biosimilar Market Attractiveness Index, By Diseases

6.    Global Biosimilar Market, By Region

6.1.    Introduction

6.1.1.    Annual Growth Rate Comparison, By Region

6.1.2.    BPS Analysis, By Region

6.2.    Market Revenue (US$Mn) Forecast, By Region

6.2.1.    North America

6.2.2.    Latin America

6.2.3.    Europe

6.2.4.    Asia Pacific

6.2.5.    Middle East

6.2.6.    Africa

6.3.    Global Biosimilar Market Attractiveness Index, By Region

7.    North America Biosimilar Market Analysis and Forecast, 2020–2028

7.1.    Introduction

7.1.1.    Annual Growth Rate Comparison, By Country

7.1.2.    BPS Analysis, By Country

7.2.    Market Revenue (US$Mn) Forecast, By Country

7.2.1.    U.S. Biosimilar Market

7.2.2.    Canada Biosimilar Market

7.3.    North America Biosimilar Market, By Product Type

7.3.1.    Recombinant Non-Glycosylated Proteins

7.3.2.    Recombinant Human Growth Hormone (RHGH)

7.3.3.    Granulocyte Colony-Stimulating Factor (Filgrastim)

7.3.4.    Insulin

7.3.5.    Interferons

7.3.5.1.    Interferon-Beta

7.3.5.2.    Interferon-Alpha

7.3.6.    Recombinant Glycosylated Proteins

7.3.6.1.    Erythropoietin (EPO)

7.3.6.2.    Monoclonal Antibodies (MABS)

7.3.6.2.1.    Infliximab

7.3.6.2.2.    Rituximab

7.3.6.2.3.    Adalimumab

7.3.6.2.4.    Other Monoclonal Antibodies

7.3.6.3.    Follitropin

7.3.7.    Recombinant Peptides

7.3.7.1.    Glucagon

7.3.7.2.    Calcitonin

7.4.    North America Biosimilar Market, By Type of Manufacturing

7.4.1.    In-House Manufacturing

7.4.2.    Contract Manufacturing

7.5.    North America Biosimilar Market, By Diseases

7.5.1.    Oncology

7.5.2.    Chronic Disease

7.5.3.    Autoimmune Disorder

7.5.4.    Blood Disorders

7.5.5.    Growth Hormone Disorders

7.5.6.    Infectious Disorder

7.5.7.    Others

7.6.    North America Biosimilar Market Attractiveness Index

7.6.1.    By Country

7.6.2.    By Product Type

7.6.3.    By Type of Manufacturing

7.6.4.    By Diseases

8.    Latin America Biosimilar Market Analysis and Forecast, 2020–2028

8.1.    Introduction

8.1.1.    Annual Growth Rate Comparison, By Country

8.1.2.    BPS Analysis, By Country

8.2.    Market (US$Mn) Forecast, By Country

8.2.1.    Brazil Biosimilar Market

8.2.2.    Mexico Biosimilar Market

8.2.3.    Argentina Biosimilar Market

8.2.4.    Rest of Latin America Biosimilar Market

8.3.    Latin America Biosimilar Market, By Product Type

8.3.1.    Recombinant Non-Glycosylated Proteins

8.3.2.    Recombinant Human Growth Hormone (RHGH)

8.3.3.    Granulocyte Colony-Stimulating Factor (Filgrastim)

8.3.4.    Insulin

8.3.5.    Interferons

8.3.5.1.    Interferon-Beta

8.3.5.2.    Interferon-Alpha

8.3.6.    Recombinant Glycosylated Proteins

8.3.6.1.    Erythropoietin (EPO)

8.3.6.2.    Monoclonal Antibodies (MABS)

8.3.6.2.1.    Infliximab

8.3.6.2.2.    Rituximab

8.3.6.2.3.    Adalimumab

8.3.6.2.4.    Other Monoclonal Antibodies

8.3.6.3.    Follitropin

8.3.7.    Recombinant Peptides

8.3.7.1.    Glucagon

8.3.7.2.    Calcitonin

8.4.    Latin America Biosimilar Market, By Type of Manufacturing

8.4.1.    In-House Manufacturing

8.4.2.    Contract Manufacturing

8.5.    Latin America Biosimilar Market, By Diseases

8.5.1.    Oncology

8.5.2.    Chronic Disease

8.5.3.    Autoimmune Disorder

8.5.4.    Blood Disorders

8.5.5.    Growth Hormone Disorders

8.5.6.    Infectious Disorder

8.5.7.    Others

8.6.    Latin America Biosimilar Market Attractiveness Index

8.6.1.    By Country

8.6.2.    By Product Type

8.6.3.    By Type of Manufacturing

8.6.4.    By Diseases

9.    Europe Biosimilar Market Analysis and Forecast, 2020–2028

9.1.    Introduction

9.1.1.    Annual Growth Rate Comparison, By Country

9.1.2.    BPS Analysis, By Country

9.2.    Market (US$Mn) Forecast, By Country

9.2.1.    U.K. Biosimilar Market

9.2.2.    Germany Biosimilar Market

9.2.3.    Italy Biosimilar Market

9.2.4.    France Biosimilar Market

9.2.5.    Spain Biosimilar Market

9.2.6.    Russia Biosimilar Market

9.2.7.    Poland Biosimilar Market

9.2.8.    BENELUX Biosimilar Market

9.2.9.    NORDIC Biosimilar Market

9.2.10.    Rest of Europe Biosimilar Market

9.3.    Europe Biosimilar Market, By Product Type

9.3.1.    Recombinant Non-Glycosylated Proteins

9.3.2.    Recombinant Human Growth Hormone (RHGH)

9.3.3.    Granulocyte Colony-Stimulating Factor (Filgrastim)

9.3.4.    Insulin

9.3.5.    Interferons

9.3.5.1.    Interferon-Beta

9.3.5.2.    Interferon-Alpha

9.3.6.    Recombinant Glycosylated Proteins

9.3.6.1.    Erythropoietin (EPO)

9.3.6.2.    Monoclonal Antibodies (MABS)

9.3.6.2.1.    Infliximab

9.3.6.2.2.    Rituximab

9.3.6.2.3.    Adalimumab

9.3.6.2.4.    Other Monoclonal Antibodies

9.3.6.3.    Follitropin

9.3.7.    Recombinant Peptides

9.3.7.1.    Glucagon

9.3.7.2.    Calcitonin

9.4.    Europe Biosimilar Market, By Type of Manufacturing

9.4.1.    In-House Manufacturing

9.4.2.    Contract Manufacturing

9.5.    Europe Biosimilar Market, By Diseases

9.5.1.    Oncology

9.5.2.    Chronic Disease

9.5.3.    Autoimmune Disorder

9.5.4.    Blood Disorders

9.5.5.    Growth Hormone Disorders

9.5.6.    Infectious Disorder

9.5.7.    Others

9.6.    Europe Biosimilar Market Attractiveness Index

9.6.1.    By Country

9.6.2.    By Product Type

9.6.3.    By Type of Manufacturing

9.6.4.    By Diseases

10.    Asia Pacific Biosimilar Market Analysis and Forecast, 2020–2028

10.1.    Introduction

10.1.1.    Annual Growth Rate Comparison, By Country

10.1.2.    BPS Analysis, By Country

10.2.    Market (US$Mn) Forecast, By Country

10.2.1.    China Biosimilar Market

10.2.2.    India Biosimilar Market

10.2.3.    Japan Biosimilar Market

10.2.4.    Australia and New Zealand Biosimilar Market

10.2.5.    South Korea Biosimilar Market

10.2.6.    ASEAN Biosimilar Market

10.2.7.    Rest of Asia Pacific Biosimilar Market

10.3.    Asia Pacific Biosimilar Market, By Product Type

10.3.1.    Recombinant Non-Glycosylated Proteins

10.3.2.    Recombinant Human Growth Hormone (RHGH)

10.3.3.    Granulocyte Colony-Stimulating Factor (Filgrastim)

10.3.4.    Insulin

10.3.5.    Interferons

10.3.5.1.    Interferon-Beta

10.3.5.2.    Interferon-Alpha

10.3.6.    Recombinant Glycosylated Proteins

10.3.6.1.    Erythropoietin (EPO)

10.3.6.2.    Monoclonal Antibodies (MABS)

10.3.6.2.1.    Infliximab

10.3.6.2.2.    Rituximab

10.3.6.2.3.    Adalimumab

10.3.6.2.4.    Other Monoclonal Antibodies

10.3.6.3.    Follitropin

10.3.7.    Recombinant Peptides

10.3.7.1.    Glucagon

10.3.7.2.    Calcitonin

10.4.    Asia Pacific Biosimilar Market, By Type of Manufacturing

10.4.1.    In-House Manufacturing

10.4.2.    Contract Manufacturing

10.5.    Asia Pacific Biosimilar Market, By Diseases

10.5.1.    Oncology

10.5.2.    Chronic Disease

10.5.3.    Autoimmune Disorder

10.5.4.    Blood Disorders

10.5.5.    Growth Hormone Disorders

10.5.6.    Infectious Disorder

10.5.7.    Others

10.6.    Asia Pacific Biosimilar Market Attractiveness Index

10.6.1.    By Country

10.6.2.    By Product Type

10.6.3.    By Type of Manufacturing

10.6.4.    By Diseases

11.    Middle East Biosimilar Market, By Region

11.1.    Introduction

11.1.1.    Annual Growth Rate Comparison, By Country

11.1.2.    BPS Analysis, By Country

11.2.    Market (US$Mn) Forecast, By Country

11.2.1.    GCC Countries Biosimilar Market

11.2.2.    Israel Biosimilar Market

11.2.3.    Oman Biosimilar Market

11.2.4.    Rest of Middle East Biosimilar Market

11.3.    Middle East Biosimilar Market, By Product Type

11.3.1.    Recombinant Non-Glycosylated Proteins

11.3.2.    Recombinant Human Growth Hormone (RHGH)

11.3.3.    Granulocyte Colony-Stimulating Factor (Filgrastim)

11.3.4.    Insulin

11.3.5.    Interferons

11.3.5.1.    Interferon-Beta

11.3.5.2.    Interferon-Alpha

11.3.6.    Recombinant Glycosylated Proteins

11.3.6.1.    Erythropoietin (EPO)

11.3.6.2.    Monoclonal Antibodies (MABS)

11.3.6.2.1.    Infliximab

11.3.6.2.2.    Rituximab

11.3.6.2.3.    Adalimumab

11.3.6.2.4.    Other Monoclonal Antibodies

11.3.6.3.    Follitropin

11.3.7.    Recombinant Peptides

11.3.7.1.    Glucagon

11.3.7.2.    Calcitonin

11.4.    Middle East Biosimilar Market, By Type of Manufacturing

11.4.1.    In-House Manufacturing

11.4.2.    Contract Manufacturing

11.5.    Middle East Biosimilar Market, By Diseases

11.5.1.    Oncology

11.5.2.    Chronic Disease

11.5.3.    Autoimmune Disorder

11.5.4.    Blood Disorders

11.5.5.    Growth Hormone Disorders

11.5.6.    Infectious Disorder

11.5.7.    Others

11.6.    Middle East Biosimilar Market Attractiveness Index

11.6.1.    By Country

11.6.2.    By Product Type

11.6.3.    By Type of Manufacturing

11.6.4.    By Diseases

12.    Africa Biosimilar Market, By Region

12.1.    Introduction

12.1.1.    Annual Growth Rate Comparison, By Country

12.1.2.    BPS Analysis, By Country

12.2.    Market (US$Mn) Forecast, By Country

12.2.1.    South Africa Biosimilar Market

12.2.2.    Egypt Biosimilar Market

12.2.3.    North Africa Biosimilar Market

12.2.4.    Rest of Africa Biosimilar Market

12.3.    Africa Biosimilar Market, By Product Type

12.3.1.    Recombinant Non-Glycosylated Proteins

12.3.2.    Recombinant Human Growth Hormone (RHGH)

12.3.3.    Granulocyte Colony-Stimulating Factor (Filgrastim)

12.3.4.    Insulin

12.3.5.    Interferons

12.3.5.1.    Interferon-Beta

12.3.5.2.    Interferon-Alpha

12.3.6.    Recombinant Glycosylated Proteins

12.3.6.1.    Erythropoietin (EPO)

12.3.6.2.    Monoclonal Antibodies (MABS)

12.3.6.2.1.    Infliximab

12.3.6.2.2.    Rituximab

12.3.6.2.3.    Adalimumab

12.3.6.2.4.    Other Monoclonal Antibodies

12.3.6.3.    Follitropin

12.3.7.    Recombinant Peptides

12.3.7.1.    Glucagon

12.3.7.2.    Calcitonin

12.4.    Africa Biosimilar Market, By Type of Manufacturing

12.4.1.    In-House Manufacturing

12.4.2.    Contract Manufacturing

12.5.    Africa Biosimilar Market, By Diseases

12.5.1.    Oncology

12.5.2.    Chronic Disease

12.5.3.    Autoimmune Disorder

12.5.4.    Blood Disorders

12.5.5.    Growth Hormone Disorders

12.5.6.    Infectious Disorder

12.5.7.    Others

12.6.    Africa Biosimilar Market Attractiveness Index

12.6.1.    By Country

12.6.2.    By Product Type

12.6.3.    By Type of Manufacturing

12.6.4.    By Diseases

13.    Recommendation

13.1.    Market Strategy

14.    Competitive Landscape

14.1.    Competition Dashboard

14.2.    List and Company Overview of Global Key Players

14.3.    Company Profiles

14.3.1.    Pfizer

14.3.1.1.    Company Overview

14.3.1.2.    Financial Overview

14.3.1.3.    Product Portfolio

14.3.1.4.    Key Developments

14.3.1.5.    Business Strategies

14.3.2.    Sandoz International

14.3.3.    Teva Pharmaceuticals

14.3.4.    Amgen

14.3.5.    Biocon

14.3.6.    Dr. Reddy’s Laboratories

14.3.7.    Celltrion

14.3.8.    Samsung Biologics

14.3.9.    Synthon Pharmaceuticals, Inc.

14.3.10.    LG Life Sciences

14.3.11.    Biocon

14.3.12.    Hospira

14.3.13.    Merck Serono (Merck Group)

14.3.14.    Biogen idec Inc.

14.3.15.    Genentech (Roche Group)

15.    Acronyms